Quince Therapeutics
NASDAQ: QNCXSouth San Francisco, US · Founded 2012 · California corporation · 2 known investors
Biotech
Founders & leadership
CR
Charles RyanExecutive Officer
BH
Brendan HannahExecutive Officer
DT
Dirk ThyeExecutive Officer, Director
SD
Stephen DominyDirector
CL
Casey LynchExecutive Officer, Director
KG
Kristen GafricExecutive Officer
IZ
Ilan ZipkinDirector
DL
David LamondDirector
UR
Una RyanDirector
CS
Christopher SennerDirector
MM
Margi McLoughlinDirector
JB
June BrayDirector
Investors · 2
Reported raises · per SEC filings
Form D private placements▶$7.4MofferedJun 2026 · 66 investors · BiotechnologyRule 506(b)
▶$7.4MofferedJun 2026 · 66 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David LamondDirector
- Christopher SennerDirector
- Charles RyanExecutive Officer
- Brendan HannahExecutive Officer
- Dirk ThyeExecutive Officer, Director
- Brigette RobertsExecutive Officer, Director
- June BrayDirector
- Offering amount
- $7.4M
- Sales commissions
- $1.8M
- Placement agents
- LifeSci Capital
- First sale
- May 2026
- Incorporated
- Corporation, California
- Federal exemptions
- 06b
▶$114.7MraisedJun 2026 · 27 investors · BiotechnologyRule 506(b)
▶$114.7MraisedJun 2026 · 27 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
- Dirk ThyeExecutive Officer, Director
- June BrayDirector
- Brendan HannahExecutive Officer
- Brigette RobertsExecutive Officer, Director
- Charles RyanExecutive Officer
- Christopher SennerDirector
- David LamondDirector
- Offering amount
- $186.4M
- Amount sold
- $114.7M
- Sales commissions
- $7.9M
- Placement agents
- LifeSci Capital
- First sale
- May 2026
- Incorporated
- Corporation, California
- Federal exemptions
- 06b
▶$11.5MraisedJul 2025 · 15 investors · BiotechnologyRule 506(b)
▶$11.5MraisedJul 2025 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Una RyanDirector
- David LamondDirector
- Christopher SennerDirector
- Charles RyanExecutive Officer
- Margi McLoughlinDirector
- June BrayDirector
- Luca BenattiDirector
- Brendan HannahExecutive Officer
- Dirk ThyeExecutive Officer, Director
- Rajiv PatniDirector
- Offering amount
- $21.9M
- Amount sold
- $11.5M
- Sales commissions
- $689.3K
- Placement agents
- Citizens JMP Securities, LLC
- First sale
- Jun 2025
- Incorporated
- Corporation, California
- Federal exemptions
- 06b
▶$84.5MraisedMay 2018 · 36 investors · PharmaceuticalsRule 506(b)
▶$84.5MraisedMay 2018 · 36 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ilan ZipkinDirector
- Roger QuyDirector
- David LamondDirector
- Kristen GafricExecutive Officer
- Margi McLoughlinDirector
- Casey LynchExecutive Officer, Director
- Stephen DominyDirector
- Offering amount
- $85.6M
- Amount sold
- $84.5M
- First sale
- May 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.6MraisedFeb 2017 · 8 investors · PharmaceuticalsRule 506(b)
▶$7.6MraisedFeb 2017 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Stephen A. DominyDirector
- Casey LynchExecutive Officer, Director
- David LamondDirector
- Ilan ZipkinDirector
- Roger QuyDirector
- Margi McLoughlinDirector
- Kristen GafricExecutive Officer
- Offering amount
- $8M
- Amount sold
- $7.6M
- First sale
- Feb 2017
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$7.9MraisedJan 2016 · 13 investors · PharmaceuticalsRule 506(b)
▶$7.9MraisedJan 2016 · 13 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Stephen DominyDirector
- Casey LynchExecutive Officer, Director
- Margi McLoughlinDirector
- Kristen GafricExecutive Officer
- David LamondDirector
- Ilan ZipkinDirector
- Offering amount
- $15.9M
- Amount sold
- $7.9M
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
- Form PRE 14A Quince Therapeutics Inc For: 1 August By Investing.comng.investing.com · 2026
- Form S-3 Quince Therapeutics For: 31 July By Investing.comca.investing.com · 2026
- Quince Therapeutics outlines Orphai deal and major dilution | QNCX SEC Filing - Form PRE 14Astocktitan.net · 2026
- Quince Therapeutics (QNCX) acquires Orphai and secures up to $187M PIPEstocktitan.net · 2026
- Quince Therapeutics Closes Orphai Deal and Secures Funding - TipRanks.comtipranks.com · 2026